This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aust, G. Articles by Hoang-Vu, C. Search for Related Content PubMed PubMed Citation Articles by Aust, G. Articles by Hoang-Vu, C.

CD97: A Dedifferentiation Marker in Human Thyroid Carcinomas¹

Department of Internal Medicine III [G. A., S. L., W. A. S.], Department of Genetics [W. E.], and Institute of Clinical Immunology and Transfusion Medicine [I. L.], University of Leipzig, Ph.-Rosenthal-Strasse 27, D-04103 Leipzig, Germany; Department of Pathology, University of Uppsala, S-75185 Uppsala, Sweden [N-E. H.], and Klinik für Allgemeinchirurgie, Martin-Luther-Universität, Halle-Wittenberg, D-06097 Halle, Germany [O. L., H. D., C. H-V.]

CD97 is a dimeric glycoprotein of M_r 75,000–85,000 and 28,000 belonging to a novel subfamily of seven-span transmembrane region leukocyte cell surface molecules. It is expressed abundantly in cells of hematopoietic origin. This is the first report demonstrating the expression of CD97 outside the hematopoetic system. CD97 was studied in normal human and neoplastic follicular epithelium of the thyroid and anaplastic (n = 3) and papillary (n = 1) thyroid carcinoma cell lines. In normal thyroid tissue (n = 11), no immunoreactivity of CD97 could be found, whereas in differentiated thyroid carcinomas (n = 10), CD97 expression was either lacking or low. Eleven of 12 undifferentiated anaplastic carcinomas revealed high CD97 presentation. CD97 was absent or only weakly present in patients with postoperative T₁ tumors but increased greatly with the progression to postoperative T₄ tumors. CD97 is clearly present in thyroid carcinoma cell lines but only at a very low level in normal human thyrocytes. Quantitation of CD97 cell surface expression levels revealed that C 643 and SW 1736 cells showed a two to four times higher specific antibody-binding capacity than did 8505 C and HTh 74 cells and a nearly 20 times higher specific antibody-binding capacity than normal thyrocytes. Phorbol 12-myristate 13-acetate treatment progressively caused a decrease of CD97 antigen expression in all cell lines to about 30% of their initial levels after 48 h. Immunohistochemical staining of SW 1736 cells revealed that CD97 is located in most of the cell compartments and suggested a CD97 internalization process after phorbol 12-myristate 13-acetate treatment. Semiquantitative reverse transcription-PCR showed a correlation of CD97 mRNA and cell surface CD97 expression level in the cell lines. SW 1736, HTh 74, and 8505 C cells apparently expressed CD97 with alternative glycosylation compared to peripheral lymphocytes, whereas most of the CD97 antigen presented on thyrocytes and C 643 cells had glycosylation sites resembling those of lymphocytes. The data suggest that CD97 expression may be a sensitive marker of dedifferentiation and of lymph node involvement in human thyroid tumors.

¹ This study was supported by Grant Sche 225/10-2 from Deutsche Forschungsgemeinschaft and Grant 01 ZZ 9512 from Bundesministerium für Bildung und Forschung (BMBF) and in part by Deutsche Krebshilfe.

² To whom requests for reprints should be addressed. Phone: 49-341-9713317; Fax: 49-341-9713219.

Received 9/30/96. Accepted 2/28/97.

This article has been cited by other articles:

				T. Wang, Y. Ward, L. Tian, R. Lake, L. Guedez, W. G. Stetler-Stevenson, and K. Kelly CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells Blood, April 1, 2005; 105(7): 2836 - 2844. [Abstract] [Full Text] [PDF]

				T. Mustafa, A. Eckert, T. Klonisch, A. Kehlen, P. Maurer, M. Klintschar, M. Erhuma, R. Zschoyan, O. Gimm, H. Dralle, et al. Expression of the Epidermal Growth Factor Seven-Transmembrane Member CD97 Correlates with Grading and Staging in Human Oral Squamous Cell Carcinomas Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 108 - 119. [Abstract] [Full Text] [PDF]

				J. C. Leemans, A. A. te Velde, S. Florquin, R. J. Bennink, K. de Bruin, R. A. W. van Lier, T. van der Poll, and J. Hamann The Epidermal Growth Factor-Seven Transmembrane (EGF-TM7) Receptor CD97 Is Required for Neutrophil Migration and Host Defense J. Immunol., January 15, 2004; 172(2): 1125 - 1131. [Abstract] [Full Text] [PDF]

				M. Steinert, M. Wobus, C. Boltze, A. Schutz, M. Wahlbuhl, J. Hamann, and G. Aust Expression and Regulation of CD97 in Colorectal Carcinoma Cell Lines and Tumor Tissues Am. J. Pathol., November 1, 2002; 161(5): 1657 - 1667. [Abstract] [Full Text] [PDF]

				M. Stacey, G.-W. Chang, S. L. Sanos, L. R. Chittenden, L. Stubbs, S. Gordon, and H.-H. Lin EMR4, a Novel Epidermal Growth Factor (EGF)-TM7 Molecule Up-regulated in Activated Mouse Macrophages, Binds to a Putative Cellular Ligand on B Lymphoma Cell Line A20 J. Biol. Chem., August 2, 2002; 277(32): 29283 - 29293. [Abstract] [Full Text] [PDF]

				M. J. Kwakkenbos, G.-W. Chang, H.-H. Lin, W. Pouwels, E. C. de Jong, R. A. W. van Lier, S. Gordon, and J. Hamann The human EGF-TM7 family member EMR2 is a heterodimeric receptor expressed on myeloid cells J. Leukoc. Biol., May 1, 2002; 71(5): 854 - 862. [Abstract] [Full Text] [PDF]

				M. C. Specht, O. N. Tucker, M. Hocever, D. Gonzalez, L. Teng, and T. J. Fahey III Cyclooxygenase-2 Expression in Thyroid Nodules J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 358 - 363. [Abstract] [Full Text] [PDF]

				L. Ludwig, H. Kessler, M. Wagner, C. Hoang-Vu, H. Dralle, G. Adler, B. O. Bohm, and R. M. Schmid Nuclear Factor-{{kappa}}B Is Constitutively Active in C-Cell Carcinoma and Required for RET-induced Transformation Cancer Res., June 1, 2001; 61(11): 4526 - 4535. [Abstract] [Full Text] [PDF]

				W. Eichler CD97 isoform expression in leukocytes J. Leukoc. Biol., October 1, 2000; 68(4): 561 - 567. [Abstract] [Full Text]

				A. Y. Liu Differential Expression of Cell Surface Molecules in Prostate Cancer Cells Cancer Res., July 1, 2000; 60(13): 3429 - 3434. [Abstract] [Full Text]

				W. Voigt, A. Bulankin, T. Müller, C. Schoeber, A. Grothey, C. Hoang-Vu, and H-J. Schmoll Schedule-dependent Antagonism of Gemcitabine and Cisplatin in Human Anaplastic Thyroid Cancer Cell Lines Clin. Cancer Res., May 1, 2000; 6(5): 2087 - 2093. [Abstract] [Full Text]

				C. Hoang-Vu, K. Bull, I. Schwarz, G. Krause, C. Schmutzler, G. Aust, J. Köhrle, and H. Dralle Regulation of CD97 Protein in Thyroid Carcinoma J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 1104 - 1109. [Abstract] [Full Text]